Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia

Leukemia

Volumn 18, Issue 4, 2004, Pages 720-726

  Muller Tidow C ^a   Metzelder, S K ^a   Buerger, H ^a   Packeisen, J ^b   Ganser, A ^c   Heil, G ^c   Kugler K ^a   Adiguzel G ^a   Schwable J ^a   Steffen, B ^a   Ludwig, W D ^d   Heinecke, A ^a   Buchner T ^a   Berdel, W E ^a   Serve, H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Institute of Pathology   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

AML; Cyclins; Cyclins A1; Leukemia; p14ARF; Prognosis; Protein expression; Tumor suppressor

Indexed keywords

CYCLIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MESSENGER RNA; MITOXANTRONE; MYC PROTEIN; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P16; TIOGUANINE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN P53; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STEM CELL TRANSPLANTATION; TUMOR SUPPRESSOR GENE; ACUTE DISEASE; BONE MARROW; CASE CONTROL STUDY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; SURVIVAL;

ACUTE DISEASE; ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; CELL CYCLE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16544371074     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403296     Document Type: Article

References (22)

1. Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61: 647-653.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60: 3689-3695.
4. Büchner T, Hiddemann W, Wormann B, Löffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116-4124.
5. Müller C, Readhead C, Diederichs S, Idos G, Yang R, Tidow N et al. Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol 2000; 20: 3316-3329.
6. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999; 59: 2759-2765.
7. Brandt B, Roetger A, Bidart JM, Packeisen J, Schier K, Mikesch JH et al. Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2 -positive cells with high invasion potential. Cancer Res 2002; 62: 1020-1024.
8. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
9. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
10. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol 2001; 21: 3789-3806.
11. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
12. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002; 12: 53-59.
13. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
14. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
15. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
16. Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8: 743-750.
17. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12: 2434-2442.
18. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976-1982.
19. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Cancer Leukemia Group B (CALGB 8461) et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
20. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996; 73: 610-614.
21. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653-699.
22. Fugazza G, Bruzzone R, Puppo L, Patrone F, Sessarego M. Amplified c-MYC sequences localized by fluorescence in situ hybridization on double minute chromosomes in acute myeloid leukemias. Leukemia Res 1997; 21: 703-709.